D-Nome is a technology company.
D-Nome has raised $2.0M across 1 funding round.
D-Nome has raised $2.0M in total across 1 funding round.
D-Nome is a health-tech startup founded in 2021 and based in Hyderabad, India, specializing in cell-free synthetic biology for rapid, accurate, and scalable molecular diagnostics.[1][2][3] It develops the proprietary D-LAMP platform—an enzyme mix enabling nucleic acid amplification at room temperature (37°C) without specialized equipment—targeting healthcare providers, diagnostic kit manufacturers, and research institutions facing limitations in traditional methods like complexity, time, and infrastructure needs.[2][3][4][5] The company has raised approximately $1.5M from investors including Entrepreneur First, Ankur Capital, Campus Fund, Rebalance, and Impact India Investment Partners, with a small team of 6 employees driving growth in democratizing genomics-based testing.[2][6]
This SaaS-enabled solution addresses critical gaps in diagnostic data management and analysis, particularly in resource-limited settings, by simplifying processes and reducing reliance on labs and skilled personnel.[1][2][5]
D-Nome emerged in 2021 from Hyderabad, Telangana, India, as a deep-tech venture at the AIC-CCMB incubator (3rd Floor, AIC-CCMB, Uppal), founded by a team backed early by Entrepreneur First.[2][3][4] The idea stemmed from recognizing flaws in conventional molecular diagnostics—such as slow speed, inaccuracy, and scalability issues in resource-constrained environments—prompting the creation of cell-free synthetic biology tools like D-LAMP for "deviceless" testing.[2][5] Early traction came via portfolio inclusion in Entrepreneur First's network and seed funding totaling $1.5M, fueling development of platform applications beyond diagnostics.[2][3][6] Pivotal moments include refining D-LAMP for room-temperature use, positioning it as a next-generation alternative to PCR sequencing diagnostics.[4][5][6]
D-Nome rides the global surge in synthetic biology and point-of-care diagnostics, accelerated by pandemics highlighting needs for fast, decentralized testing amid rising chronic diseases and antimicrobial resistance.[2][3] Timing aligns with India's health-tech boom—fueled by government initiatives like AIC incubators and investor focus on deep-tech—and falling genomics costs, making scalable solutions viable.[1][3][6] Market forces like resource-limited healthcare in emerging economies favor its deviceless model, influencing the ecosystem by enabling affordable genomics for startups, labs, and global health equity.[2][5]
D-Nome's momentum—$1.5M funding, D-LAMP refinements, and EF backing—positions it for partnerships with diagnostic manufacturers and expansion into sequencing or multi-disease kits.[2][4][6] Trends like AI-integrated synth-bio and decentralized health (e.g., wearables, at-home tests) will shape its path, potentially scaling to 10x growth via international pilots. Its influence may evolve from niche innovator to ecosystem enabler, amplifying accessible diagnostics as synth-bio matures, tying back to its core mission of decoding genomics efficiently.[3][5]
D-Nome has raised $2.0M in total across 1 funding round.
D-Nome's investors include Ankur Capital.
D-Nome has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2023 | $2.0M Seed | Ankur Capital |